Literature DB >> 8397258

Characterization of CTLA-4 structure and expression on human T cells.

T Lindsten1, K P Lee, E S Harris, B Petryniak, N Craighead, P J Reynolds, D B Lombard, G J Freeman, L M Nadler, G S Gray.   

Abstract

CTLA-4 is an adhesion receptor expressed on activated T cells. The amino acid sequence of CTLA-4 is related to CD28, and although the function of CTLA-4 remains unknown, it shares several features with CD28, including a common counter-receptor, B7, that is present on Ag-presenting cells. In a recent study we found that CD28 and CTLA-4 were coexpressed at the mRNA level on activated T cells but that only CD28 was expressed on resting T cells. Here we show that within the T cell population, CTLA-4 expression is restricted to the subset of T cells that also express cell surface CD28. CTLA-4 mRNA expression can be induced on quiescent T cells via phorbol ester-mediated activation of protein kinase C but not with calcium ionophore treatment alone. Phorbol ester-induced expression of CTLA-4 mRNA could be enhanced with calcium ionophore treatment, and treatment of cells in this manner resulted in a reciprocal decrease in expression of CD28 mRNA. Ligation of CD28 with monoclonal antibody also resulted in the specific and rapid induction of CTLA-4 mRNA. To study the expression of CTLA-4 at the protein level, a rabbit antiserum against a recombinant protein derived from CTLA-4 cDNA was generated. When activated T cells were labeled with [35S]methionine, the rabbit antiserum precipitated a 41- to 43-kDa protein from whole cell lysates. Similar results were found when detergent-soluble lysates from 125I surface-labeled resting and activated T cells were analyzed by SDS-PAGE. Surprisingly, under the conditions tested, CTLA-4 migrated primarily as a monomer at the cell surface, and could not be shown to exist as a disulfide-bonded homodimer or as a heterodimer consisting of CTLA-4 and CD28. These results suggest that B7 can bind to T cells via distinct receptor complexes consisting of either CD28 or CTLA-4, and that these complexes may potentially mediate distinct biologic functions. Further, the present results suggest that noncovalent interactions might mediate association of CTLA-4 and/or CD28 at the cell surface.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8397258

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  85 in total

Review 1.  Immunomodulation by interference with co-stimulatory molecules: therapeutic perspectives in asthma.

Authors:  S E Burastero; G A Rossi
Journal:  Thorax       Date:  1999-06       Impact factor: 9.139

2.  Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells.

Authors:  Xuguang Tai; François Van Laethem; Leonid Pobezinsky; Terry Guinter; Susan O Sharrow; Anthony Adams; Larry Granger; Michael Kruhlak; Tullia Lindsten; Craig B Thompson; Lionel Feigenbaum; Alfred Singer
Journal:  Blood       Date:  2012-03-07       Impact factor: 22.113

Review 3.  Immunotherapies for bladder cancer: a new hope.

Authors:  Farhad Fakhrejahani; Yusuke Tomita; Agnes Maj-Hes; Jane B Trepel; Maria De Santis; Andrea B Apolo
Journal:  Curr Opin Urol       Date:  2015-11       Impact factor: 2.309

4.  The association of CTLA-4 and HLA class II autoimmune risk genotype with regulatory T cell marker expression in 5-year-old children.

Authors:  C-O Jonson; M Hedman; M Karlsson Faresjö; R Casas; J Ilonen; J Ludvigsson; O Vaarala
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

5.  Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma.

Authors:  Ajay V Maker; James C Yang; Richard M Sherry; Suzanne L Topalian; Udai S Kammula; Richard E Royal; Marybeth Hughes; Michael J Yellin; Leah R Haworth; Catherine Levy; Tamika Allen; Sharon A Mavroukakis; Peter Attia; Steven A Rosenberg
Journal:  J Immunother       Date:  2006 Jul-Aug       Impact factor: 4.456

6.  Abatacept does not induce direct gene expression changes in antigen-presenting cells.

Authors:  Julie A Carman; Patricia M Davis; Wen-Pin Yang; Jun Zhu; Han Chang; Aiqing He; Amy Truong; Suzanne J Suchard; Steven G Nadler
Journal:  J Clin Immunol       Date:  2009-03-04       Impact factor: 8.317

7.  Engineering Bacillus subtilis as a Versatile and Stable Platform for Production of Nanobodies.

Authors:  Mengdi Yang; Ge Zhu; George Korza; Xin Sun; Peter Setlow; Jiahe Li
Journal:  Appl Environ Microbiol       Date:  2020-04-01       Impact factor: 4.792

8.  Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.

Authors:  Stephanie G Downey; Jacob A Klapper; Franz O Smith; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Tamika E Allen; Catherine L Levy; Michael Yellin; Geoffrey Nichol; Donald E White; Seth M Steinberg; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2007-11-02       Impact factor: 12.531

9.  Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity.

Authors:  Nitya Jain; Hai Nguyen; Cynthia Chambers; Joonsoo Kang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

Review 10.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.